Frazier Healthcare Partners has closed Frazier Healthcare Growth Buyout Fund VIII, LP at the hard cap of $525 million. The new fund will invest in profitable healthcare companies in the lower middle market. Investors in Fund VIII include both existing and new limited partners such as endowments, public and private pension funds and financial institutions.
Frazier Healthcare invests from $20 million to $50 million in buyouts, recapitalizations or corporate carve-outs of healthcare services and biopharma companies that have between $5 million and $40 million of EBITDA. Target acquisitions can be located anywhere in the United States, Canada and Europe. With the new closing, the firm now has over $2.9 billion of capital under management across eight funds. Frazier Healthcare has offices in Seattle and Menlo Park (www.frazierhealthcare.com).
“We are appreciative of the continued support from our existing limited partners and pleased to selectively add a few new blue chip investors,” said Nader Naini, managing general partner at Frazier Healthcare Partners. “The team is particularly gratified that this world-class investor group recognized our rich, 25-year history of developing category-leading healthcare companies in the lower middle market.”
The investment and portfolio management activities of Fund VIII will be run out of the firm’s Seattle office. As an aside, Frazier’s life sciences team, based in Menlo Park, recently closed on an early-stage therapeutics focused fund with $262 million in capital commitments.
Since its founding in 1991, Frazier has made investments in more than 170 companies ranging from early-stage venture investments to growth buyouts of profitable lower middle market companies.
© 2016 Private Equity Professional • Private Equity’s Leading News Magazine • 3-24-16